Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma
c-Src is a tyrosine kinase belonging to the Src-family kinases. It is overexpressed and/or hyperactivated in a variety of cancer cells, thus its inhibition has been predicted to have therapeutic effects in solid tumors. Recently, the pyrazolo[3,4-d]pyrimidine 3 was reported as a dual c-Src/Abl inhibitor. Herein we describe a multidisciplinary drug discovery approach for the optimization of the lead 3 against c-Src. Starting from the X-ray crystal structure of c-Src in complex with 3, Monte Carlo free energy perturbation calculations were applied to guide the design of c-Src inhibitors with improved activities. As a result, the introduction of a meta hydroxyl group on the C4 anilino ring was computed to be particularly favorable. The potency of the synthesized inhibitors was increased with respect to the starting lead 3. The best identified compounds were also found active in the inhibition of neuroblastoma cell proliferation. Furthermore, compound 29 also showed in vivo activity in xenograft model using SH-SY5Y cells..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Journal of medicinal chemistry - 58(2015), 1, Seite 347 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tintori, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1967096880 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1967096880 | ||
| 003 | DE-627 | ||
| 005 | 20220222133422.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1967096880 | ||
| 035 | |a (DE-599)GBVOLC1967096880 | ||
| 035 | |a (PRQ)p833-405fccaf81ad535aceb1b5236716a457dc353e051c65f66db17767f47e0e30680 | ||
| 035 | |a (KEY)0068637920150000058000100347combiningxraycrystallographyandmolecularmodelingto | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.42 |2 bkl | ||
| 100 | 1 | |a Tintori, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a c-Src is a tyrosine kinase belonging to the Src-family kinases. It is overexpressed and/or hyperactivated in a variety of cancer cells, thus its inhibition has been predicted to have therapeutic effects in solid tumors. Recently, the pyrazolo[3,4-d]pyrimidine 3 was reported as a dual c-Src/Abl inhibitor. Herein we describe a multidisciplinary drug discovery approach for the optimization of the lead 3 against c-Src. Starting from the X-ray crystal structure of c-Src in complex with 3, Monte Carlo free energy perturbation calculations were applied to guide the design of c-Src inhibitors with improved activities. As a result, the introduction of a meta hydroxyl group on the C4 anilino ring was computed to be particularly favorable. The potency of the synthesized inhibitors was increased with respect to the starting lead 3. The best identified compounds were also found active in the inhibition of neuroblastoma cell proliferation. Furthermore, compound 29 also showed in vivo activity in xenograft model using SH-SY5Y cells. | ||
| 650 | 4 | |a src-Family Kinases - chemistry | |
| 650 | 4 | |a Pyrazoles - chemistry | |
| 650 | 4 | |a Cell Cycle - drug effects | |
| 650 | 4 | |a Pyrimidines - chemistry | |
| 650 | 4 | |a Protein Kinase Inhibitors - chemistry | |
| 650 | 4 | |a Pyrazoles - pharmacology | |
| 650 | 4 | |a Pyrimidines - metabolism | |
| 650 | 4 | |a Protein Kinase Inhibitors - pharmacology | |
| 650 | 4 | |a Cell Proliferation - drug effects | |
| 650 | 4 | |a src-Family Kinases - antagonists & inhibitors | |
| 650 | 4 | |a Neuroblastoma - pathology | |
| 650 | 4 | |a Protein Kinase Inhibitors - metabolism | |
| 650 | 4 | |a Neuroblastoma - drug therapy | |
| 650 | 4 | |a Pyrimidines - pharmacology | |
| 650 | 4 | |a src-Family Kinases - metabolism | |
| 700 | 1 | |a Fallacara, Anna Lucia |4 oth | |
| 700 | 1 | |a Radi, Marco |4 oth | |
| 700 | 1 | |a Zamperini, Claudio |4 oth | |
| 700 | 1 | |a Dreassi, Elena |4 oth | |
| 700 | 1 | |a Crespan, Emmanuele |4 oth | |
| 700 | 1 | |a Maga, Giovanni |4 oth | |
| 700 | 1 | |a Schenone, Silvia |4 oth | |
| 700 | 1 | |a Musumeci, Francesca |4 oth | |
| 700 | 1 | |a Brullo, Chiara |4 oth | |
| 700 | 1 | |a Richters, André |4 oth | |
| 700 | 1 | |a Gasparrini, Francesca |4 oth | |
| 700 | 1 | |a Angelucci, Adriano |4 oth | |
| 700 | 1 | |a Festuccia, Claudio |4 oth | |
| 700 | 1 | |a Delle Monache, Simona |4 oth | |
| 700 | 1 | |a Rauh, Daniel |4 oth | |
| 700 | 1 | |a Botta, Maurizio |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d Easton, Pa. : American Chemical Society, 1963 |g 58(2015), 1, Seite 347 |w (DE-627)129545201 |w (DE-600)218133-2 |w (DE-576)014995336 |x 0022-2623 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2015 |g number:1 |g pages:347 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25469771 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_2005 | ||
| 936 | b | k | |a 44.42 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 58 |j 2015 |e 1 |h 347 | ||